In addition, TUFM is upregulated at the protein level in prostate cancer [42,43], and ACPP has been used as a diagnostic and prognostic marker together with prostate-specific antigen (PSA) for prostate cancer. This evidence concerns the gene ACP3 and prostate carcinoma.